Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • Peer reviewer login
  • Alerts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • Peer reviewer login
  • Alerts
  • Subscriptions

Fluticasone/formoterol combined in a single aerosol inhaler vs budesonide/formoterol for the treatment of asthma: A non-inferiority trial

Anna Bodzenta-Lukaszyk, Roland Buhl, Beatrix Bálint, Mark Lomax, Kay Spooner
European Respiratory Journal 2011 38: p894; DOI:
Anna Bodzenta-Lukaszyk
1Department of Allergology and Internal Medicine, Medical University of Bialystok, Bialystok, Poland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Roland Buhl
2Pulmonary Department, Mainz University Hospital, Mainz, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Beatrix Bálint
3Department of Pulmonary Diseases, Csongrád County Municipal Hospital, Deszk, Hungary
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mark Lomax
4European Medical Science, Mundipharma Research Ltd., Cambridge, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kay Spooner
5European Medical Operations, Mundipharma Research Ltd., Cambridge, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
Loading

Abstract

Background: Fluticasone (FLUT) and formoterol (FORM) are widely prescribed for asthmatics. A combination of FLUT/FORM in a single aerosol inhaler (flutiform®) has now been developed. This trial aimed to determine if FLUT/FORM is non-inferior to budesonide/formoterol (BUD/FORM; single inhaler) with regards to efficacy, and to assess safety, in adolescents and adults with moderate-to-severe persistent reversible asthma.

Methods: Eligible patients had an FEV1 of ≥50% to ≥80% for predicted normal values and a ≥15% reversibility in FEV1 following salbutamol (up to 400μg). 279 patients were randomised to FLUT/FORM 250/10μg b.i.d. (n=140) or BUD/FORM 400/12μg b.i.d. (n=139) in this 12 week, double-blind, 2-arm, parallel-group trial. The primary efficacy measure was change in morning pre-dose FEV1 from baseline to Week 12.

Results: 261 patients completed (FLUT/FORM; n=133; BUD/FORM; n=128). Both treatment groups showed improvements in morning pre-dose FEV1 from baseline to Week 12. FLUT/FORM was shown to be non-inferior to BUD/FORM because the lower limit of the 95% CI of the treatment difference (FLUT/FORM – BUD/FORM) was greater than the pre-defined threshold value of -0.2L (95% CI: -0.130, 0.043L). One patient on FLUT/FORM discontinued due to AEs (asthma exacerbation: not related) vs 3 patients on BUD/FORM (asthma exacerbation, acute sinusitis: not related; asthma exacerbation: possibly related).

Conclusions: Fluticasone/formoterol combination improved morning pre-dose FEV1 over 12 weeks of treatment; demonstrated comparable efficacy to BUD/FORM with regards to this key lung function measure of asthma control and had a similar safety profile.

  • © 2011 ERS
Previous
Back to top
Vol 38 Issue Suppl 55 Table of Contents
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Fluticasone/formoterol combined in a single aerosol inhaler vs budesonide/formoterol for the treatment of asthma: A non-inferiority trial
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Fluticasone/formoterol combined in a single aerosol inhaler vs budesonide/formoterol for the treatment of asthma: A non-inferiority trial
Anna Bodzenta-Lukaszyk, Roland Buhl, Beatrix Bálint, Mark Lomax, Kay Spooner
European Respiratory Journal Sep 2011, 38 (Suppl 55) p894;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Fluticasone/formoterol combined in a single aerosol inhaler vs budesonide/formoterol for the treatment of asthma: A non-inferiority trial
Anna Bodzenta-Lukaszyk, Roland Buhl, Beatrix Bálint, Mark Lomax, Kay Spooner
European Respiratory Journal Sep 2011, 38 (Suppl 55) p894;
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo

Jump To

  • Article
  • Info & Metrics
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • Functional effects of long term ICS treatment in controlled asthma
  • Anti-immunoglobulin E antibodies may improve remodeling in a mouse model of asthma
  • Montelukast plus inhaled budesonide versus double dose inhaled budesonide in nonasthmatic eosinophilic bronchitis
Show more 97. Asthma: control and treatment

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2023 by the European Respiratory Society